The Middle East and Africa Autoimmune Diagnostics Market was worth USD 0.58 billion in 2018 and estimated to reach USD 0.68 billion by the end of 2023 with a growing potential of 3.108%.Autoimmune diseases are an active hyper immune response against its own body tissues and cells. Due to merger and acquisition that provide an increasing opportunity in this region. The most common auto immune diseases include rheumatoid arthritis, type 1 diabetes, and multiple sclerosis.
The Middle East & Africa market is driven by increasing prevalence of auto immune disorders improving healthcare infrastructure. Cost issues and problems of skilled manpower are the factor that hinder the growth of the market.
The Middle East & Africa Auto immune diagnostics Market is broadly categorized based on Test type into Complete Blood Count (CBC), Autoantibody Tests, Antinuclear Antibody Tests, C - reactive protein (CRP), Comprehensive Metabolic panel, Urinalysis, Erythrocyte Sedimentation Rate (ESR) and others.
Based on Disease type the market is categorized into Localized auto immune disease diagnostics and systemic auto immune disease diagnostics. Local auto immune disease diagnostics is further classified into Graves’ disease, Hashimoto's Thyroiditis, Type 1 diabetes, Multiple Sclerosis, Psoriasis and Others. Systemic auto immune disease diagnostics is categorized into Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and Ankylosing Spondylitis.
Based on End users into Hospitals, Research centres, and diagnostic laboratories and on the basis of geography, the Middle East & Africa Auto Immune Diagnostics market is analysed under various regions namely Middle East and Africa.
Some of the major players influencing the Middle East & Africa Autoimmune diagnostics market are Bio-Rad, Siemens Healthcare, Abbott Laboratories, Crescendo Bioscience, Roche Diagnostics SQI Diagnostics, AESKU Diagnostics, INOVA Diagnostics Inc., BioMerieux SA, Beckman Coulter Inc., Hemagen Diagnostics, Quest Diagnostics, Eli lilly, Glaxosmithkline Plc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Test Type
5.1.1 Autoantibody Tests
5.1.2 Antinuclear Antibody Tests
5.1.3 Complete Blood Count (CBC)
5.1.4 C - reactive protein (CRP)
5.1.5 Comprehensive Metabolic panel
5.1.6 Urinalysis
5.1.7 Erythrocyte Sedimentation Rate (ESR)
5.1.8 Others
5.2 By Disease Type
5.2.1 Localized auto immune disease diagnostics
5.2.1.1 Graves' Disease
5.2.1.2 Hashimoto's Thyroiditis
5.2.1.3 Multiple Sclerosis
5.2.1.4 Type 1 diabetes
5.2.1.5 Psoriasis
5.2.1.6 Others
5.2.2 Systemic auto immune disease diagnostics
5.2.2.1 Rheumatoid Arthritis (RA)
5.2.2.2 Ankylosing Spondylitis
5.2.2.3 Systemic Lupus Erythematosus (SLE)
5.3 By End Users
5.3.1 Hospitals
"5.3.2 Research centers
"
5.3.3 Diagnostic laboratories
6. Geographical Analysis
6.1 Introduction
6.2 Middle-East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Bio-Rad
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Siemens Healthcare
8.3 Abbott Laboratories
8.4 Crescendo Bioscience
8.5 Roche Diagnostics
8.6 SQI Diagnostics
8.7 AESKU Diagnostics
8.8 INOVA Diagnostics
8.9 BioMerieux SA
8.10 Beckman Coulter Inc.
8.11 Hemagen Diagnostics
8.12 Quest Diagnostics
8.13 Eli lilly
8.14 Glaxosmithkline Plc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
